Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $10.00 for the company, according to Zacks. Zacks has also given Adamis Pharmaceuticals Corp. an industry rank of 93 out of 265 based on the ratings given to related companies.
Separately, Maxim Group reissued a “buy” rating and issued a $10.00 target price on shares of Adamis Pharmaceuticals Corp. in a research report on Monday, August 29th.
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) opened at 3.11 on Wednesday. The stock’s market cap is $64.96 million. Adamis Pharmaceuticals Corp. has a 52 week low of $2.50 and a 52 week high of $10.98. The company has a 50-day moving average price of $3.08 and a 200-day moving average price of $4.79.
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Adamis Pharmaceuticals Corp. by 21.8% in the second quarter. Vanguard Group Inc. now owns 335,814 shares of the specialty pharmaceutical company’s stock valued at $940,000 after buying an additional 60,197 shares during the period. Walleye Trading LLC increased its position in Adamis Pharmaceuticals Corp. by 118.1% in the second quarter. Walleye Trading LLC now owns 275,078 shares of the specialty pharmaceutical company’s stock valued at $770,000 after buying an additional 148,966 shares during the period. Finally, BlackRock Fund Advisors increased its position in Adamis Pharmaceuticals Corp. by 24.7% in the second quarter. BlackRock Fund Advisors now owns 49,806 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 9,868 shares during the period. 9.70% of the stock is currently owned by institutional investors.
About Adamis Pharmaceuticals Corp.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).